- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Cholesterol Prevalence Has Declined Significantly Over Time, CDC Reports
From 1999-2000 to 2015-2016, there has been a declining trend in high total cholesterol among adults in the United States, according to a report from the CDC. From 2007-2008 to 2015-2016 there was also a decline in low high-density cholesterol. Both types of cholesterol are risk factors for cardiovascular disease, which remains the leading cause of death in the United States.
From 1999-2000 to 2015-2016, there has been a declining trend in high total cholesterol among adults in the United States, according to a report from the CDC. From 2007-2008 to 2015-2016 there was also a decline in low high-density (HDL) cholesterol. Both types of cholesterol are risk factors for cardiovascular disease, which remains the leading cause of death in the United States.
The report on cholesterol in US adults found that 12.4% of adults had a high total cholesterol during 2015-2016. This represents a significant decline in total cholesterol from 18.3% in 1999-2000. In addition, low HDL cholesterol significantly declined from 22.2% in 2007-2008 to 18.4% in 2015-2016. For both high total cholesterol and low HDL cholesterol the change from 2013-2014 to 2015-2016 was not significant.
Adults between the ages of 40 to 59 had a higher prevalence of high total cholesterol (17.1%) compared with younger adults between the ages of 20 and 39 (7.9%) and older adults age 60 and over (12.5%). Overall, men had a higher prevalence at 25.8% compared with 8.9% of women.
The prevalence of low HDL cholesterol followed similar trends with people between the ages of 40 and 59 having the highest prevalence (20.1%), but younger adults had a higher prevalence (19.2%) than older adults (14.5%). Again, men had a higher prevalence than women (29.5% vs 8.9%).
The report also looked at high total cholesterol and HDL cholesterol by race and found that there were no statistically significant differences in prevalence of high total cholesterol either overall or among men when looking at race and Hispanic origin. The prevalence of low HDL cholesterol was higher in Hispanic adults (24.7%) compared with non-Hispanic whites, non-Hispanic blacks, and non-Hispanic Asians with similar patterns for men and women.
For high total cholesterol, there was a higher prevalence among non-Hispanic whites (14.8%) compared with Hispanics (9%).
“As part of its objectives to improve the health of the US population, Healthy People 2020 has included the goal of reducing the proportion of adults with high total blood cholesterol to less than 13.5%,” the report concluded.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
